AzTrials
AzTrials

Chronic PeriodontitisPhase 2NCT01921738

The Effect of Azithromycin in the Treatment of Chronic Periodontitis

A Phase 2 study testing 1% Azithromycin gel and Azithromycin in people with Chronic Periodontitis, run by Isfahan University of Medical Sciences at 1 site in Iran.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to investigate the effects of Azithromycin (systemic and locally) on the clinical and microbiological parameters of periodontal in patients with chronic periodontitis. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Chronic Periodontitis
What is being tested?
1% Azithromycin gel and Azithromycin
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
80 participants
Where
1 siteIran
Study dates
May 2012to Apr 2013
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with moderate to severe chronic periodontitis
  • At least twenty teeth
  • Age over 18 years

Who cannot join

  • With Systemic diseases that affect periodontal conditions such as: diabetes, blood disorders and diseases of immune system
  • History of antibiotic therapy within the 4 months prior to study
  • History of Allergy to the macrolide group of antibiotics
  • Smoking
  • The lack of patient cooperation
  • History of periodontal treatment during the 4 months prior to the trial
Show all 9Show fewer
  • Pregnancy
  • Lactating females
  • Patients treated with drugs such as: Anti-acid, Warfarin and Cyclisporine 10) Alcohol use.

Trial locations and contacts

1 site in 1 country.

Iran1 site
  • School of Dentistry, Isfahan University of Medical Sciences

    Isfahan, Isfahan, 81746-73461

Other trials in Iran

About this study

Official title: The Effects of Systemic and Locally Azithromycin Adjunct to Scaling and Root Planning on Clinical and Microbiological Periodontal Indices in Moderate to Severe Chronic Periodontitis

The aim of this study is to investigate the effects of Azithromycin (systemic and locally) on the clinical and microbiological parameters of periodontal in patients with chronic periodontitis.

Read the detailed description

The double-blind, placebo-controlled clinical trial that is carried out in eighty patients who referred to the Department of Periodontology, Isfahan School of Dentistry. Main inclusion criteria were: 1) Patients with moderate to severe chronic periodontitis 2) At least twenty teeth 3) Age over 18 years. Main exclusion criteria were: 1) History of allergy to the macrolide group 2) History of antibiotic therapy within the 4 months ago 3) The lack of patient cooperation. For all patients is initially performed scaling and root planning (SRP). Oral health education is given to all patients. After one month, patients are randomly divided into four equal groups (two test groups and two control groups). Azithromycin(AZM) 250 milligram (mg) capsules, two times a day (bid), for three days will be given to a test group. In the other test group, 1% AZM gel is locally injected into the periodontal pockets in single-root teeth. Placebo capsules with the same dose and frequency will be given to a control group. In the other control group, placebo gel is injected in the same places. Clinical parameters included pocket depth (PD), clinical attachment level (CAL), papillary bleeding index (PBI), and periodontal disease index (PDI), which are recorded at baseline (before SRP), at 1, 2, 3 and 4 months after treatment. Using polymerase chain reaction (PCR), microbiological assessment of the percentage of Porphyromonas gingivalis (P.g) and Actinobacillus actinomycetemcomitans (A.a) are randomly done for 40 patients (10 patients from each group) at baseline and at 3 months after the treatment.

Being tested
1% Azithromycin gel, Azithromycin, placebo gel, placebo capsule
Keywords
Chronic Periodontitis, Azithromycin, SRP
Medical subject headings
Chronic Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 1% Azithromycin gelDrug

    Also called Avindo Gel (Azithromycin Gel 1%), serial number: 8904069410010

    Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.

  • AzithromycinDrug

    Also called Zithromax (Zimexir, Exir, Brojerd, Iran), serial number: 6260153032097

    Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)

  • placebo gelDrug

    Also called carbopol 934P/974P

    Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.

  • placebo capsuleDrug

    Also called sugar capsule

    Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.

Study groups in NCT01921738
Study groupRoleWhat they receive
1% Azithromycin gelExperimentalParticipants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
Receives: Drug: 1% Azithromycin gel
Azithromycin capsuleExperimentalParticipants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
Receives: Drug: Azithromycin
Placebo GelPlacebo comparatorParticipants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
Receives: Drug: placebo gel
placebo capsulePlacebo comparatorParticipants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
Receives: Drug: placebo capsule

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from baseline in Periodontal Pocket Depth

    measurement was done with color coded periodontal probe (Nordent).

    Measured: at one, two, three and four months after the intervention.

  2. Change from baseline in Clinical Attachment Level

    measurement was done with color coded periodontal probe (Nordent).

    Measured: at one, two, three and four months after the intervention.

  3. Change from baseline in Modified Gingival Index

    visual scale, according to Lobene classification.

    Measured: at one, two, three and four months after the intervention.

  4. Change from baseline in Papillary Bleeding Index

    measurement was done with color coded periodontal probe (Nordent), according to (Muhlemann and Saxer) classification.

    Measured: at one, two, three and four months after the intervention.

  5. Change from baseline in Porphyromonas gingivalis count

    measurement was done with Real Time PCR (Primer Design kits).

    Measured: at three months after the intervention

  6. Change from baseline in Actinobacillus actinomycetemcomitans count

    measurement was done with Real Time PCR (Primer Design kits).

    Measured: at three months after the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2013 (estimated)
  2. Study startMay 2012
  3. Primary completionMar 2013
  4. Study completionApr 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01921738
Sponsor's protocol ID
mnts-o77
Status last verified
Aug 2013
First submitted
8 Aug 2013
Last updated
13 Aug 2013
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing 1% Azithromycin gel and Azithromycin in people with Chronic Periodontitis, run by Isfahan University of Medical Sciences at 1 site in Iran.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from baseline in Periodontal Pocket Depth (time frame: at one, two, three and four months after the intervention.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in